MX2019005321A - Derivados de prostaglandina que liberan oxido nitrico para el tratamiento de glaucoma de tension normal. - Google Patents

Derivados de prostaglandina que liberan oxido nitrico para el tratamiento de glaucoma de tension normal.

Info

Publication number
MX2019005321A
MX2019005321A MX2019005321A MX2019005321A MX2019005321A MX 2019005321 A MX2019005321 A MX 2019005321A MX 2019005321 A MX2019005321 A MX 2019005321A MX 2019005321 A MX2019005321 A MX 2019005321A MX 2019005321 A MX2019005321 A MX 2019005321A
Authority
MX
Mexico
Prior art keywords
nitric oxide
normal tension
tension glaucoma
oxide releasing
prostaglandin derivatives
Prior art date
Application number
MX2019005321A
Other languages
English (en)
Inventor
Lamar Vittitow Jason
Elizabeth Cavet Megan
Original Assignee
Bausch & Lomb
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bausch & Lomb filed Critical Bausch & Lomb
Publication of MX2019005321A publication Critical patent/MX2019005321A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • C07C405/0008—Analogues having the carboxyl group in the side-chains replaced by other functional groups
    • C07C405/0041—Analogues having the carboxyl group in the side-chains replaced by other functional groups containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Esta invencion proporciona un metodo para reducir la presion intraocular en un paciente que tiene glaucoma de tension normal, que comprende poner en contacto un ojo de un sujeto que tiene glaucoma de tension normal con una composicion farmaceutica que comprende una cantidad efectiva de derivados de prostaglandina que liberan oxido nitrico de la formula (I).
MX2019005321A 2016-11-08 2017-11-07 Derivados de prostaglandina que liberan oxido nitrico para el tratamiento de glaucoma de tension normal. MX2019005321A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662419153P 2016-11-08 2016-11-08
PCT/EP2017/078486 WO2018087092A1 (en) 2016-11-08 2017-11-07 Nitric oxide releasing prostaglandin derivatives for treating normal tension glaucoma

Publications (1)

Publication Number Publication Date
MX2019005321A true MX2019005321A (es) 2019-10-14

Family

ID=60421748

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019005321A MX2019005321A (es) 2016-11-08 2017-11-07 Derivados de prostaglandina que liberan oxido nitrico para el tratamiento de glaucoma de tension normal.

Country Status (7)

Country Link
US (1) US11058691B2 (es)
JP (1) JP7055802B2 (es)
KR (1) KR20190104993A (es)
BR (1) BR112019009330A2 (es)
CA (1) CA3043000A1 (es)
MX (1) MX2019005321A (es)
WO (1) WO2018087092A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6750473B2 (ja) * 2016-11-22 2020-09-02 沖電気工業株式会社 自動取引装置及び自動取引システム
WO2023041182A1 (en) 2021-09-20 2023-03-23 Nicox Sa Nitric oxide releasing prostamide as neuroprotective agent
CA3195291A1 (en) * 2022-04-13 2023-10-13 Caravel Therapeutics, Inc. Preservative-free ophthalmic pharmaceutical emulsion and its application
WO2024121867A1 (en) * 2022-12-09 2024-06-13 Sentiss Pharma Private Limited Pharmaceutical composition for glaucoma and ocular hypertension

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4952581A (en) 1987-04-03 1990-08-28 The Trustees Of Columbia University In The City Of New York Use of a prostaglandin in combination with an adrenergic blocking agent for reduction of intraocular pressure
EP0664707B1 (en) 1992-10-13 1997-06-04 Alcon Laboratories, Inc. Combinations of prostaglandins and clonidine derivatives for the treatment of glaucoma
IT1295694B1 (it) 1996-11-14 1999-05-27 Nicox Sa Nitrossi derivati per la preparazione di medicamenti ad attivita antitrombinica
WO2005068421A1 (en) * 2004-01-05 2005-07-28 Nicox, S.A. Prostaglandin nitrooxyderivatives
CA2613010A1 (en) 2005-06-29 2007-01-04 Pfizer Inc. Fluoroprostaglandins nitroderivatives
CA2613748A1 (en) 2005-06-29 2007-01-04 Pfizer Inc. Prostaglandin derivatives
AR076731A1 (es) 2008-05-09 2011-07-06 Pfizer Prostamidas donadoras de oxido nitrico, uso de los mismos y composiciones farmaceuticas

Also Published As

Publication number Publication date
CA3043000A1 (en) 2018-05-17
KR20190104993A (ko) 2019-09-11
JP2019534296A (ja) 2019-11-28
JP7055802B2 (ja) 2022-04-18
BR112019009330A2 (pt) 2019-07-30
US11058691B2 (en) 2021-07-13
US20200179401A1 (en) 2020-06-11
WO2018087092A1 (en) 2018-05-17

Similar Documents

Publication Publication Date Title
MX2019005321A (es) Derivados de prostaglandina que liberan oxido nitrico para el tratamiento de glaucoma de tension normal.
PH12018500658A1 (en) Methods of treating intraocular pressure with activators of tie-2
PH12016502382A1 (en) Substituted indazole compounds as irak4 inhibitors
MY171920A (en) Prevention and treatment of ocular conditions
PH12019501902A1 (en) Ocular formulations for drug-delivery to the posterior segment of the eye
BR112017000774A2 (pt) dispositivo e método de distribuição de implante ocular
MX2019005934A (es) Compuestos de benzodiazolio como inhibidores del canal de sodio epitelial (enac).
NZ704266A (en) Inhibitors of alpha-crystallin aggregation for the treatment for cataract
MY186271A (en) Ophthalmic compositions and methods of use therefor
MX355853B (es) Composicion oftalmica para el tratamiento de infeccion ocular.
MX2022006229A (es) Composiciones y metodos para el tratamiento de resistencia a la insulina.
MX2022003892A (es) Soluciones intracamerales antiinflamatorias y midriaticas para inhibicion de condiciones inflamatorias oculares postoperatorias.
MX2017004819A (es) Metodos de tratamiento de transtornos urológicos usando sarm.
MX2019011925A (es) Conjugados y derivados de prostaglandina para tratar el glaucoma y la hipertension ocular.
MY198753A (en) Treatment of androgen deprivation therapy associated symptoms
PL3720428T3 (pl) Kompozycja oftalmiczna do podawania miejscowego zawierająca kwas dobezylowy do leczenia chorób tylnego odcinka oka
PH12017501560A1 (en) Tetrahydropyranyl benzamide derivatives
MX2016006256A (es) Tratamiento de glaucoma usando laquinimod.
TR201902864T4 (tr) Beta-klorosiklopentanların hidrofilik ester ön ilaçlarının kullanımı ile azaltılmış merkezi korneal kalınlaşma.
BR112017007102A2 (pt) uso de um medicamento no tratamento de patologias da córnea, composição oftálmica para uso de um medicamento no tratamento de doenças da córnea e método para preparar a composição oftálmica
EP2650021A4 (en) MEDICAL DEVICE FOR CONTROLLED RELEASE OF MEDICAMENT
GR1008527B (el) Οφθαλμικο φαρμακευτικο σκευασμα ελευθερο συντηρητικου περιεχον βιματοπροστη
EA201790231A1 (ru) Профилактическое или терапевтическое средство для лечения болезней заднего сегмента глаза
UA85479U (ru) Способ лечения глаукомы в эксперименте
GR1008250B (el) Οφθαλμικο σκευασμα αναλογου προσταγλανδινης και μεθοδος παρασκευης αυτου